Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Oncology Specialties, Alabama |
---|---|
Information provided by: | Oncology Specialties, Alabama |
ClinicalTrials.gov Identifier: | NCT00225056 |
In this phase II study, we plan to evaluate the efficacy, safety and tolerability of weekly docetaxel and capecitabine on a 21-day cycle followed by maintenance single agent capecitabine for the treatment of metastatic breast cancer, Based on the efficacy and toxicity of the combination regimen dosages previously reviewed; weekly docetaxel 30mg/m2 on days 1 and 8 plus capecitabine 1600mg/m2 (800mg/m2 orally twice daily)on day 1 through 14 of each cycle will be utilized.
Condition | Intervention | Phase |
---|---|---|
Metastatic Breast Cancer |
Drug: docetaxel and capecitabine |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma |
Ages Eligible for Study: | 19 Years to 85 Years |
Genders Eligible for Study: | Female |
Inclusion Criteria:
Exclusion Criteria:
United States, Alabama | |
Comprehensive Cancer Institute | |
Huntsville, Alabama, United States, 35801 |
Principal Investigator: | John M Waples, MD | Oncology Specialties, PC |
Study ID Numbers: | CCIBRE02 |
Study First Received: | September 21, 2005 |
Last Updated: | April 18, 2007 |
ClinicalTrials.gov Identifier: | NCT00225056 |
Health Authority: | United States: Food and Drug Administration |
Docetaxel Capecitabine Skin Diseases |
Breast Neoplasms Breast Diseases Carcinoma |
Antimetabolites Neoplasms Antimetabolites, Antineoplastic Neoplasms by Site |
Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Therapeutic Uses Pharmacologic Actions |